Semaglutide mimics the action of the GLP-1 hormone, stimulating insulin release and reducing glucagon secretion. This improves glycaemic control, reduces appetite and promotes weight loss.
Recommended for:
Studies:
Clinical trials (SUSTAIN, STEP) demonstrated Semaglutide’s ability to reduce HbA1c, lower body weight and improve cardiovascular outcomes.
Administered subcutaneously once a week. The dosage is determined individually by a doctor, starting with the lowest and gradually increasing.
Contraindications:
Side effects:









